The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...